On April 30, 2026 ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, reported that new data from the Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals’ zanidatamab (ZIIHERA) in heavily pretreated patients with HER2-positive metastatic breast cancer (mBC) will be presented at the ESMO (Free ESMO Whitepaper) Breast Cancer 2026 Congress in Berlin on May 7.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ESMO (Free ESMO Whitepaper) Breast Cancer poster presentation will highlight data from exploratory analyses conducted to identify biomarkers predictive of response to the evorpacept + zanidatamab regimen.
The Company also announced it will report first quarter 2026 financial results on Friday, May 8, 2026, before market open. Management will host a conference call at 8:30 a.m. ET to review Q1 financial results, and guest speaker Sara Hurvitz, M.D., Professor, Senior Vice President and Director, Clinical Research Division and Smith Family Endowed Chair in Women’s Health at Fred Hutchinson Cancer Center, will discuss and share her perspective on the ESMO (Free ESMO Whitepaper) Breast Cancer clinical data.
The ESMO (Free ESMO Whitepaper) Breast Cancer presentation will feature data from an exploratory biomarker analysis of patients with HER2-positive mBC in the evorpacept + zanidatamab Phase 1b/2 trial. Topline data from this analysis, which ALX Oncology announced in January 2026, indicate that the responses were largely restricted to patients with higher CD47 expression. These results reinforce data from the ASPEN-06 clinical trial, which previously demonstrated that CD47 expression could potentially serve as an important predictive biomarker for response and durable benefit in patients with advanced gastric cancer who retained HER2 expression.
ESMO Breast Cancer 2026 Presentation Details
Title: Exploratory biomarker analysis from a phase 1b/2 trial of zanidatamab + evorpacept in patients with HER2-positive metastatic breast cancer
Date & Time: Thursday, May 7, 2026, 7:15 am ET / 13:15 CEST
Abstract Number: 561
Poster Number: 72P
Presenter: Funda Meric-Bernstam, MD, Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center
Q1 2026 Results Conference Call and Webcast Details
Date & Time: Friday, May 8, 2026, 8:30 am ET
Guest Speaker: Sara Hurvitz, MD, Professor, Senior Vice President and Director, Clinical Research Division and Smith Family Endowed Chair in Women’s Health at Fred Hutchinson Cancer Center; Professor and Head, Division of Hematology and Oncology, Department of Medicine, University of Washington
Webcast Access: View Source;tp_key=2800839c82
Participant Listening Options by Phone: To access the conference call, please dial 1-877-407-0752 or +1-201-389-0912 and ask to be joined into the ALX Oncology First Quarter 2026 Financial Results Conference Call.
Another option for instant telephone access to the event is to use the Call Me link below:
View Source;passcode=13755276&h=true&info=company&r=true&B=6
A live audio webcast of the call, along with the ALX Oncology corporate presentation, will be available under "Events & Presentations" in the Investor section of the Company’s website, www.alxoncology.com. An archived webcast will be available on the Company’s website after the event.
(Press release, ALX Oncology, APR 30, 2026, View Source [SID1234664958])